LU92000I2 - Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables - Google Patents

Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables

Info

Publication number: LU92000I2
Authority: LU; Luxembourg
Prior art keywords: renal; diabetic; pharmaceutically acceptable; acceptable salt; disease
Prior art date: 2002-05-17

Application number

LU92000C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2012-05-14

Publication date

2012-07-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92000(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-14 Application filed by Novartis Ag filed Critical Novartis Ag

2012-07-16 Publication of LU92000I2 publication Critical patent/LU92000I2/fr

Links

150000003839 salts Chemical class 0.000 title 3
UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title 1
229960004601 aliskiren Drugs 0.000 title 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title 1
229960000528 amlodipine Drugs 0.000 title 1
229960002003 hydrochlorothiazide Drugs 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 abstract 4
206010019280 Heart failures Diseases 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
206010002383 Angina Pectoris Diseases 0.000 abstract 2
229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 2
208000001647 Renal Insufficiency Diseases 0.000 abstract 2
239000000480 calcium channel blocker Substances 0.000 abstract 2
201000006370 kidney failure Diseases 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
206010003662 Atrial flutter Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
208000010159 IgA glomerulonephritis Diseases 0.000 abstract 1
206010021263 IgA nephropathy Diseases 0.000 abstract 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
201000009623 Myopathy Diseases 0.000 abstract 1
208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
208000003782 Raynaud disease Diseases 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
206010039710 Scleroderma Diseases 0.000 abstract 1
206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
208000032594 Vascular Remodeling Diseases 0.000 abstract 1
206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
238000009825 accumulation Methods 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
230000001627 detrimental effect Effects 0.000 abstract 1
208000033679 diabetic kidney disease Diseases 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
210000002744 extracellular matrix Anatomy 0.000 abstract 1
230000003176 fibrotic effect Effects 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
201000010260 leiomyoma Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000008312 primary pulmonary hypertension Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
201000001474 proteinuria Diseases 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
201000002793 renal fibrosis Diseases 0.000 abstract 1
239000002461 renin inhibitor Substances 0.000 abstract 1
229940086526 renin-inhibitors Drugs 0.000 abstract 1
208000037812 secondary pulmonary hypertension Diseases 0.000 abstract 1
210000000329 smooth muscle myocyte Anatomy 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

LU92000C 2002-05-17 2012-05-14 Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables LU92000I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38154602P	2002-05-17	2002-05-17
PCT/EP2003/005188 WO2003097098A1 (fr)	2002-05-17	2003-05-16	Composition pharmaceutique comprenant un inhibiteur de renine, un agent de blocage du canal du calcium et un diuretique

Publications (1)

Publication Number	Publication Date
LU92000I2 true LU92000I2 (fr)	2012-07-16

Family

ID=29550141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92000C LU92000I2 (fr)	2002-05-17	2012-05-14	Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables

Country Status (24)

Country	Link
US (3)	US20050182042A1 (fr)
EP (2)	EP2316488A1 (fr)
JP (2)	JP5288678B2 (fr)
KR (3)	KR20100137026A (fr)
CN (1)	CN1655819A (fr)
AT (1)	ATE520417T1 (fr)
AU (1)	AU2003240669B2 (fr)
BR (1)	BR0310084A (fr)
CA (1)	CA2485081C (fr)
CY (2)	CY1112013T1 (fr)
DK (1)	DK1507558T3 (fr)
EC (1)	ECSP045428A (fr)
ES (1)	ES2369216T3 (fr)
IL (1)	IL164837A (fr)
LU (1)	LU92000I2 (fr)
MX (1)	MXPA04011383A (fr)
NO (1)	NO334382B1 (fr)
NZ (1)	NZ536555A (fr)
PL (1)	PL219032B1 (fr)
PT (1)	PT1507558E (fr)
RU (1)	RU2316318C2 (fr)
SI (1)	SI1507558T1 (fr)
WO (1)	WO2003097098A1 (fr)
ZA (1)	ZA200408442B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
KR20100137026A (ko) *	2002-05-17	2010-12-29	노파르티스 아게	레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
WO2004110354A2 (fr)	2003-05-15	2004-12-23	Roskamp Research, Llc	Methode de reduction d'un depot amyloide, neurotoxicite amyloide et microgliose
TW200538154A (en) *	2004-02-17	2005-12-01	Novartis Ag	Combination of organic compounds
RU2426532C2 (ru) *	2004-03-17	2011-08-20	Новартис Аг	Применение органических соединений
MY144477A (en) *	2004-03-17	2011-09-30	Novartis Ag	Galenic formulations of organic compounds
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
RU2385156C2 (ru) *	2004-05-31	2010-03-27	Лабораториос Альмираль С.А.	Комбинации, содержащие антимускариновые средства и кортикостероиды
MY146830A (en) *	2005-02-11	2012-09-28	Novartis Ag	Combination of organic compounds
MX2007011697A (es) *	2005-03-22	2007-11-16	Novartis Ag	Biomarcadores para eficacia de aliskiren como agente hipertensivo.
EP1951309A2 (fr) *	2005-11-08	2008-08-06	Novartis AG	Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) *	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
EP1891937A1 (fr) *	2006-08-25	2008-02-27	Novartis AG	Formulations galéniques de l'aliskiren
US8119841B2 (en) *	2006-11-07	2012-02-21	Novartis Ag	Crystalline forms of aliskiren hemifumarate
EP2089356B1 (fr) *	2006-11-09	2012-04-25	Novartis AG	Sel d'aliskirène avec de l'acide orotique
JP5220025B2 (ja) *	2006-12-04	2013-06-26	プロメディオール，インコーポレイテッド	線維症疾患を処置するための併用療法
JP2010518147A (ja) *	2007-02-16	2010-05-27	ノバルティスアーゲー	有機化合物の使用
EP1972335A1 (fr) *	2007-03-23	2008-09-24	Krka	Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables
RU2363472C2 (ru) *	2007-05-22	2009-08-10	Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию"	Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию
US8497243B2 (en) *	2007-07-06	2013-07-30	Promedior, Inc.	Methods and compositions useful in the treatment of mucositis
US9884899B2 (en)	2007-07-06	2018-02-06	Promedior, Inc.	Methods for treating fibrosis using CRP antagonists
CN101883564B (zh)	2007-10-05	2013-10-16	阿尔茨海默病学会美国公司	使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
EP2062874B1 (fr)	2007-11-20	2014-12-17	KRKA, tovarna zdravil, d.d., Novo mesto	Procédé et intermédiaires pour la préparation d'aliskiren
EP2100599A1 (fr)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
RU2373932C1 (ru) *	2008-05-20	2009-11-27	Илья Николаевич Медведев	Способ коррекции уровня микровезикул в крови при артериальной гипертонии
RU2372079C1 (ru) *	2008-05-20	2009-11-10	Илья Николаевич Медведев	Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
JO3239B1 (ar)	2008-09-22	2018-03-08	Novartis Ag	تركيبات جالينية من مركبات عضوية
RU2382644C1 (ru) *	2008-11-05	2010-02-27	Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию"	Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
SI2189442T1 (sl)	2008-11-20	2015-03-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Postopek in intermediati za pripravo aliskirena
PT2405928T (pt) *	2009-03-11	2017-02-07	Promedior Inc	Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PT2405929T (pt) *	2009-03-11	2018-07-23	Promedior Inc	Métodos de tratamento para distúrbios autoimunes
UA110323C2 (en) *	2009-06-04	2015-12-25	Promedior Inc	Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) *	2009-06-17	2019-05-28	Promedior Inc	SAP-variánsok és alkalmazásuk
EP2510928A1 (fr)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
CN102247344A (zh) *	2011-05-30	2011-11-23	北京阜康仁生物制药科技有限公司	一种新型降血压组合物
CN102552277A (zh) *	2011-12-02	2012-07-11	邬林祥	氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN102626391B (zh) *	2012-04-19	2013-07-10	海南美兰史克制药有限公司	一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
GB201317373D0 (en)	2013-10-01	2013-11-13	Univ Dundee	Treatment and prevention of cancer
CN111789843A (zh) *	2019-04-08	2020-10-20	深圳奥萨医药有限公司	含氨氯地平、氯噻酮和阿米洛利的药物组合物
KR102414285B1 (ko) *	2020-06-02	2022-06-28	이화여자대학교 산학협력단	플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5350771A (en) *	1989-03-22	1994-09-27	Peter K. T. Pang	Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
US5656650A (en) *	1990-12-14	1997-08-12	Smithkline Beecham Corp.	Angiotensin II receptor blocking compositions
EP0565634B1 (fr) *	1990-12-14	1999-03-17	Smithkline Beecham Corporation	Compositions de blocage de recepteur de l'angiotensine ii
US5178877A (en) *	1991-01-04	1993-01-12	Abbott Laboratories	Encapsulated renin inhibitor composition
US5114925A (en) *	1991-01-22	1992-05-19	Merck & Co., Inc.	Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5202322A (en) *	1991-09-25	1993-04-13	Merck & Co., Inc.	Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) *	1991-09-25	1993-10-26	Merck & Co., Inc.	Quinazolinones and pyridopyrimidinones
US5292741A (en) *	1992-08-18	1994-03-08	Merck & Co., Inc.	Macrocycles incorporating quinazolinones
MY119161A (en)	1994-04-18	2005-04-30	Novartis Ag	Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0795327A1 (fr)	1996-03-13	1997-09-17	Pfizer Inc.	Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002043807A2 (fr) *	2000-12-01	2002-06-06	Novartis Ag	Combinaison de composants organiques
DE60227679D1 (de) *	2001-09-11	2008-08-28	Asahi Kasei Pharma Corp	Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen
US7019010B2 (en) *	2001-09-27	2006-03-28	Novertis Ag	Combinations
KR20100137026A (ko) *	2002-05-17	2010-12-29	노파르티스 아게	레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물

2003
- 2003-05-16 KR KR1020107028689A patent/KR20100137026A/ko not_active Ceased
- 2003-05-16 NZ NZ536555A patent/NZ536555A/en not_active IP Right Cessation
- 2003-05-16 CA CA2485081A patent/CA2485081C/fr not_active Expired - Fee Related
- 2003-05-16 SI SI200332071T patent/SI1507558T1/sl unknown
- 2003-05-16 BR BR0310084-7A patent/BR0310084A/pt not_active Application Discontinuation
- 2003-05-16 PT PT03730064T patent/PT1507558E/pt unknown
- 2003-05-16 AU AU2003240669A patent/AU2003240669B2/en not_active Ceased
- 2003-05-16 US US10/514,683 patent/US20050182042A1/en not_active Abandoned
- 2003-05-16 CN CNA03811237XA patent/CN1655819A/zh active Pending
- 2003-05-16 MX MXPA04011383A patent/MXPA04011383A/es active IP Right Grant
- 2003-05-16 RU RU2004137104/15A patent/RU2316318C2/ru not_active IP Right Cessation
- 2003-05-16 EP EP10177741A patent/EP2316488A1/fr not_active Withdrawn
- 2003-05-16 JP JP2004505094A patent/JP5288678B2/ja not_active Expired - Fee Related
- 2003-05-16 AT AT03730064T patent/ATE520417T1/de active
- 2003-05-16 KR KR1020137023159A patent/KR20130109244A/ko not_active Ceased
- 2003-05-16 ES ES03730064T patent/ES2369216T3/es not_active Expired - Lifetime
- 2003-05-16 WO PCT/EP2003/005188 patent/WO2003097098A1/fr not_active Ceased
- 2003-05-16 KR KR10-2004-7018479A patent/KR20050008717A/ko not_active Ceased
- 2003-05-16 EP EP03730064A patent/EP1507558B8/fr not_active Expired - Lifetime
- 2003-05-16 DK DK03730064.7T patent/DK1507558T3/da active
- 2003-05-16 PL PL372203A patent/PL219032B1/pl unknown
2004
- 2004-10-19 ZA ZA200408442A patent/ZA200408442B/en unknown
- 2004-10-25 IL IL164837A patent/IL164837A/en not_active IP Right Cessation
- 2004-11-12 EC EC2004005428A patent/ECSP045428A/es unknown
- 2004-12-15 NO NO20045459A patent/NO334382B1/no not_active IP Right Cessation
2008
- 2008-08-08 US US12/188,604 patent/US8183295B2/en not_active Expired - Fee Related
2010
- 2010-08-13 JP JP2010181380A patent/JP2010280708A/ja not_active Withdrawn
2011
- 2011-11-07 CY CY20111101071T patent/CY1112013T1/el unknown
- 2011-11-30 US US13/307,567 patent/US20120071470A1/en not_active Abandoned
2012
- 2012-05-14 LU LU92000C patent/LU92000I2/fr unknown
- 2012-05-14 CY CY2012011C patent/CY2012011I1/el unknown

Also Published As

Publication number	Publication date
US20050182042A1 (en)	2005-08-18
IL164837A (en)	2013-12-31
EP1507558A1 (fr)	2005-02-23
AU2003240669B2 (en)	2007-03-08
ATE520417T1 (de)	2011-09-15
PL372203A1 (en)	2005-07-11
JP2005526850A (ja)	2005-09-08
CY2012011I2 (el)	2015-11-04
DK1507558T3 (da)	2011-12-05
ECSP045428A (es)	2005-01-03
CY2012011I1 (el)	2015-11-04
WO2003097098A1 (fr)	2003-11-27
CA2485081C (fr)	2013-01-08
HK1074774A1 (en)	2005-11-25
CY1112013T1 (el)	2015-11-04
JP2010280708A (ja)	2010-12-16
NO334382B1 (no)	2014-02-24
CA2485081A1 (fr)	2003-11-27
KR20100137026A (ko)	2010-12-29
PL219032B1 (pl)	2015-03-31
ZA200408442B (en)	2006-02-22
EP2316488A1 (fr)	2011-05-04
NO20045459L (no)	2004-12-15
PT1507558E (pt)	2011-11-23
KR20130109244A (ko)	2013-10-07
RU2316318C2 (ru)	2008-02-10
US20120071470A1 (en)	2012-03-22
BR0310084A (pt)	2005-02-15
MXPA04011383A (es)	2005-02-14
EP1507558B8 (fr)	2012-02-15
CN1655819A (zh)	2005-08-17
JP5288678B2 (ja)	2013-09-11
US20080300238A1 (en)	2008-12-04
IL164837A0 (en)	2005-12-18
RU2004137104A (ru)	2005-09-10
EP1507558B1 (fr)	2011-08-17
NZ536555A (en)	2007-03-30
ES2369216T3 (es)	2011-11-28
SI1507558T1 (sl)	2011-12-30
US8183295B2 (en)	2012-05-22
KR20050008717A (ko)	2005-01-21
AU2003240669A1 (en)	2003-12-02

Publication	Publication Date	Title
EP1507558B8 (fr)	2012-02-15	Composition pharmaceutique comprenant un inhibiteur de renine, un agent de blocage du canal du calcium et un diuretique
AU2003206738C1 (en)	2020-01-30	Pharmaceutical compositions comprising valsartan and NEP inhibitors
WO2007106708A3 (fr)	2007-12-27	Combinaison de composes organiques
EP2322174A3 (fr)	2011-07-27	Utilisation combinée de valsartane et bloqueurs du canal de calcium à but thérapeutique
JP2010280708A5 (fr)	2011-10-20